Learn More About the PROSERA Study
Now enrolling: The PROSERA phase 3 study of seralutinib in adults with pulmonary arterial hypertension.
Cardiac effort is less variable than six-minute walk distance, correlates with hemodynamics and is consistent with REVEAL 2.0 risk score in a sub-study of the TORREY phase 2 PAH trial